Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00033202
NCT00033202CompletedPhase 1

Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.

Sigma-Tau Research, Inc.6 sites in 1 country30 target enrollmentStarted: March 2002Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
30
Locations
6
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound, when given as a capsule, rather than by intravenous injection.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Industry

Study Sites (6)

Loading locations...

Similar Trials

Completed
Phase 1
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.Malignant Glioma
NCT00032903Sigma-Tau Research, Inc.59
Unknown
Phase 1
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerOvarian Epithelial CancerFallopian Tube CancerPrimary Peritoneal Cancer
NCT04029909Lee's Pharmaceutical Limited12
Active, not recruiting
Not Applicable
A Phase II study of oral gimatecan ST 1481 in progressing or recurring patients with advanced epithelial ovarian, fallopian or peritoneal cancer, previously treated with platinum and taxanesAdvanced epithelial ovarian, fallopian or peritoneal cancerMedDRA version: 6.1Level: PTClassification code 10018160
EUCTR2005-000595-40-ITSIGMA-TA56
Active, not recruiting
Not Applicable
A Phase II study of oral gimatecan (ST 1481) as salvage treatment in patients with advanced or metastatic soft tissue sarcoma relapsing after anthracycline/ifosfamide-based chemotherapy regime
EUCTR2005-001951-39-DESigma Tau Industrie Farmaceutiche Riunite S.p.A.84
Active, not recruiting
Not Applicable
A Phase II study of oral gimatecan (ST 1481) in progressing or recurring patients with advanced epithelial ovarian, fallopian or peritoneal cancer, previously treated with platinum and taxanes
EUCTR2005-000595-40-DESigma Tau Industrie Farmaceutiche Riunite S.p.A.56
This is an Early Study to Investigate the... | Clinical Trial